ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda, Boryung Pharmaceutical and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Takeda×Boryung Pharmaceutical×Merck×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaBoryung PharmaceuticalMerck
studies on the registry1,7541432,455
open to participants now8623146
phase 3 studies under way441112
reach primary completion within a year47760
programswith a study of their own in two years251884

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaBoryung PharmaceuticalMerck
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%

Boryung Pharmaceutical: 8 of its 18 programs at phase 1

  1. BR1015phase 1
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR2021phase 1
  5. olaparibphase 1

and 3 more — sign in to see them all

44%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Boryung Pharmaceutical: 9 of its 18 programs at phase 2

  1. bosmolisibphase 2
  2. BR1400-1phase 2
  3. BR1400-2phase 2
  4. BR1400-3phase 2
  5. BR1400phase 2

and 4 more — sign in to see them all

50%
23%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Boryung Pharmaceutical: 1 of its 18 programs at phase 3

  1. Pioglitazonephase 3
6%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%
00%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Boryung Pharmaceutical9 readouts · 0 phase 3···

Boryung Pharmaceutical, Feb ’27: 5 programs whose next study reaches primary completion

  1. BR1400phase 2 · Feb 1 · NCT07373613
  2. BR1400-1phase 2 · Feb 1 · NCT07373613
  3. BR1400-2phase 2 · Feb 1 · NCT07373613
  4. BR1400-3phase 2 · Feb 1 · NCT07373613
  5. BR1400-4phase 2 · Feb 1 · NCT07373613
··

Boryung Pharmaceutical, May ’27: 3 programs whose next study reaches primary completion

  1. BR5402Aphase 2 · May 0 · NCT06821945
  2. BR5402Bphase 2 · May 0 · NCT06821945
  3. BR5402D-1phase 2 · May 0 · NCT06821945
···

Boryung Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion

  1. bosmolisibphase 2 · Sep 0 · NCT07180771
·
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Boryung Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 28 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionTakedaBoryung PharmaceuticalMerck
Alzheimer Diseaseall three · compare here

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Boryung Pharmaceutical in Alzheimer Disease: 1 program

  1. Pioglitazonephase 3

Their studies: Boryung Pharmaceutical’s studies of Alzheimer Disease in search

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

Takeda in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. Brentuximab Vedotinapproved, new study

Their studies: Takeda’s studies of Lymphoma, Large B-Cell, Diffuse in search

Boryung Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. bosmolisibphase 2

Their studies: Boryung Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Prostatic Neoplasmsall three · compare here

Takeda in Prostatic Neoplasms: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Prostatic Neoplasms in search

Boryung Pharmaceutical in Prostatic Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Neoplasms2 of 3 · compare here–

Boryung Pharmaceutical in Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

Boryung Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Boryung Pharmaceutical in Diabetes Mellitus, Type 2: 5 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR3006phase 1
  5. BR3409phase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiency2 of 3 · compare here

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

–

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

Carcinoma, Renal Cell2 of 3 · compare here

Takeda in Carcinoma, Renal Cell: 1 program

  1. Vinblastineapproved, new study

Their studies: Takeda’s studies of Carcinoma, Renal Cell in search

–

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Ovarian Neoplasms2 of 3 · compare here–

Boryung Pharmaceutical in Ovarian Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Ovarian Neoplasms in search

Breast Neoplasms2 of 3 · compare here–

Boryung Pharmaceutical in Breast Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Colitis, Ulcerative2 of 3 · compare here

Takeda in Colitis, Ulcerative: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Colitis, Ulcerative in search

–

Merck in Colitis, Ulcerative: 3 programs

  1. tulisokibartphase 3
  2. MK-8690phase 2
  3. MK-6194phase 2

Their studies: Merck’s studies of Colitis, Ulcerative in search

Crohn Disease2 of 3 · compare here

Takeda in Crohn Disease: 3 programs

  1. zasocitinibphase 3
  2. teduglutidephase 3
  3. ontamalimabphase 3

Their studies: Takeda’s studies of Crohn Disease in search

–

Merck in Crohn Disease: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Crohn Disease in search

Show all 28

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetTakedaBoryung PharmaceuticalMerck
COXFA4–MetforminruleMetforminrule
COXFA4L2–MetforminruleMetforminrule
GPD2–MetforminruleMetforminrule
MT-ND1–MetforminruleMetforminrule
MT-ND2–MetforminruleMetforminrule
MT-ND3–MetforminruleMetforminrule
MT-ND4–MetforminruleMetforminrule
MT-ND4L–MetforminruleMetforminrule
MT-ND5–MetforminruleMetforminrule
MT-ND6–MetforminruleMetforminrule
NDUFA1–MetforminruleMetforminrule
NDUFA10–MetforminruleMetforminrule
NDUFA11–MetforminruleMetforminrule
NDUFA12–MetforminruleMetforminrule
NDUFA13–MetforminruleMetforminrule
NDUFA2–MetforminruleMetforminrule
NDUFA3–MetforminruleMetforminrule
NDUFA5–MetforminruleMetforminrule
NDUFA6–MetforminruleMetforminrule
NDUFA7–MetforminruleMetforminrule
NDUFA8–MetforminruleMetforminrule
NDUFA9–MetforminruleMetforminrule
NDUFAB1–MetforminruleMetforminrule
NDUFAF1–MetforminruleMetforminrule
NDUFAF2–MetforminruleMetforminrule
NDUFAF3–MetforminruleMetforminrule
NDUFAF4–MetforminruleMetforminrule
NDUFB1–MetforminruleMetforminrule
NDUFB10–MetforminruleMetforminrule
NDUFB11–MetforminruleMetforminrule
NDUFB2–MetforminruleMetforminrule
NDUFB3–MetforminruleMetforminrule
NDUFB4–MetforminruleMetforminrule
NDUFB5–MetforminruleMetforminrule
NDUFB6–MetforminruleMetforminrule
NDUFB7–MetforminruleMetforminrule
NDUFB8–MetforminruleMetforminrule
NDUFB9–MetforminruleMetforminrule
NDUFC1–MetforminruleMetforminrule
NDUFC2–MetforminruleMetforminrule
NDUFS1–MetforminruleMetforminrule
NDUFS2–MetforminruleMetforminrule
NDUFS3–MetforminruleMetforminrule
NDUFS4–MetforminruleMetforminrule
NDUFS5–MetforminruleMetforminrule
NDUFS6–MetforminruleMetforminrule
NDUFS7–MetforminruleMetforminrule
NDUFS8–MetforminruleMetforminrule
NDUFV1–MetforminruleMetforminrule
NDUFV2–MetforminruleMetforminrule
NDUFV3–MetforminruleMetforminrule
A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Boryung Pharmaceutical 5 of 18 · Merck 40 of 84 programs (29 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.